JBIO
Jade Biosciences, Inc.
NASDAQ: JBIO · HEALTHCARE · BIOTECHNOLOGY
$19.35
-1.78% today
Updated 2026-07-29
Market cap
$1.22B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.63
Dividend yield
—
52W range
$7 – $28
Volume
1.2M
WallStSmart proprietary scores
26
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C8.5
Quality
A3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
10.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$48.50
+150.65%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 10.75 — safe zone
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-24.08M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 |
| Net income | $-51.51M | $-75.52M | $-69.63M | $-127.41M | $-40.37M |
| EPS | — | — | — | — | $-2.63 |
| Free cash flow | $-39.32M | $-56.92M | $-71.20M | $-94.89M | $-24.08M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Jade Biosciences, Inc. trades at $19.35. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 10.75, it sits in the safe zone.
Frequently asked questions
What is Jade Biosciences, Inc.'s stock price?
Jade Biosciences, Inc. (JBIO) trades at $19.35.
Is Jade Biosciences, Inc. overvalued?
Jade Biosciences, Inc. carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Jade Biosciences, Inc. (JBIO)?
The 12-month analyst consensus target is $48.50, about 150.6% above the current $19.35. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Jade Biosciences, Inc.'s Altman Z-Score is 10.75, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-43.72%
Beta—
50D MA$20.23
200D MA$16.25
Shares out0.06B
Float0.04B
Short ratio—
Avg volume1.2M
Performance
1 week+27.72%
1 month+62.29%
3 months+55.44%
YTD+48.09%
1 year—
3 years—
5 years—